DIXON HUBARD FEINOUR & BROWN INC/VA - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 323 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.

Quarter-by-quarter ownership
DIXON HUBARD FEINOUR & BROWN INC/VA ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2022$890,000
+10.4%
20,2180.0%0.11%
+30.9%
Q1 2022$806,000
+0.1%
20,218
+1.0%
0.08%
+3.8%
Q4 2021$805,000
+4.3%
20,018
+5.5%
0.08%
-52.4%
Q3 2021$772,000
+21.8%
18,968
+35.8%
0.16%
+24.2%
Q2 2021$634,000
-33.2%
13,968
-50.0%
0.13%
+12.8%
Q1 2021$949,000
+158.6%
27,936
+100.0%
0.12%
+24.5%
Q4 2020$367,0000.0%13,9680.0%0.09%0.0%
Q3 2020$367,000
-3.4%
13,9680.0%0.09%
-5.1%
Q2 2020$380,000
+51.4%
13,9680.0%0.10%
+16.5%
Q1 2020$251,000
+1.2%
13,9680.0%0.08%
+32.8%
Q4 2019$248,000
+14.3%
13,9680.0%0.06%
+6.7%
Q3 2019$217,000
-19.9%
13,968
-11.4%
0.06%
-22.1%
Q2 2019$271,000
+0.7%
15,762
-5.6%
0.08%
-4.9%
Q1 2019$269,000
+10.2%
16,7020.0%0.08%
-10.0%
Q4 2018$244,000
-19.5%
16,7020.0%0.09%
+7.1%
Q3 2018$303,000
+7.4%
16,7020.0%0.08%
+2.4%
Q2 2018$282,000
-16.6%
16,702
-3.1%
0.08%
-12.8%
Q1 2018$338,000
-3.2%
17,2370.0%0.09%
-1.1%
Q4 2017$349,000
+11.9%
17,237
-3.9%
0.10%
+5.6%
Q3 2017$312,000
+35.7%
17,9440.0%0.09%
+36.4%
Q2 2017$230,000
-1.3%
17,9440.0%0.07%
-4.3%
Q1 2017$233,000
+31.6%
17,9440.0%0.07%
+23.2%
Q4 2016$177,000
-18.4%
17,9440.0%0.06%
-16.4%
Q3 2016$217,00017,9440.07%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders